Approved Hospital Formulary
Add Formweb to your mobile device
Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.
Please be sure to document all clinical activities daily.
Approved Hospital Formulary
Search results for:
rifAXIMin
rifAXIMin
- Restricted Xifaxan --> Restricted to use by infectious disease, G.I. specialists or by UAB/Hospitalists (UAB/Hospitalist restricted to use after a 72 hour trial of lactulose or other frontline agent).
- Restricted Miscellaneous Program Formulary
VIEW MORE Rifamycins
Last updated: Oct. 17, 2025
The 200 mg tablet is on long-term national shortage. Total daily doses ≥ 900 mg may be automatically converted to closest dose achievable with the 550 mg tablets during the shortage (10/2025).
Infectious Indications: Formulary, restricted to use by infectious disease and G.I. specialists.
Hepatic Encephalopathy: Formulary, restricted to use by UAB or Hospitalists. Requires a 72 hour trial of lactulose or other frontline agent prior to initiation or may be initiated at time of presentation (without a 72 hr inpatient trial) for patients receiving lactulose as a home medication.
ORDERED FORMULATION
THERAPEUTIC INTERCHANGE
Xifaxan
Rifaximin
Reviewed: September 28, 2010 and February 22, 2011 and July 26, 2011 (XIFAXAN-550) and December 17, 2013 (200 mg tablet)
Updated: June 2021 (HE Restriction), Sept. 2022 (Xifaxan)